View Future GrowthINBIOGEN 過去の業績過去 基準チェック /06INBIOGENは19.6%の年平均成長率で業績を伸ばしているが、Luxury業界はdecliningで2.7%毎年増加している。売上は減少しており、年平均13.4%の割合である。主要情報19.59%収益成長率24.24%EPS成長率Luxury 業界の成長21.63%収益成長率-13.36%株主資本利益率-12.68%ネット・マージン-333.01%前回の決算情報31 Mar 2026最近の業績更新分析記事 • Nov 21Statutory Profit Doesn't Reflect How Good INBIOGEN's (KRX:101140) Earnings AreINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. We think that...Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Net income: ₩8.17b (up ₩12.6b from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.分析記事 • May 22Solid Earnings Reflect INBIOGEN's (KRX:101140) Strength As A BusinessINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. Investors are...すべての更新を表示Recent updatesNew Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (₩5.4b revenue, or US$3.6m). Market cap is less than US$100m (₩80.7b market cap, or US$53.7m).New Risk • Apr 04New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩6.3b (US$4.2m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (₩6.3b revenue, or US$4.2m). Market cap is less than US$100m (₩88.0b market cap, or US$58.2m).Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩9,800, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 10x in the Luxury industry in South Korea. Total loss to shareholders of 13% over the past three years.お知らせ • Mar 17INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South KoreaValuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩9,060, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 12x in the Luxury industry in South Korea. Total loss to shareholders of 25% over the past three years.Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,130, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 24% over the past three years.New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₩113.7b market cap, or US$78.7m).分析記事 • Nov 21Statutory Profit Doesn't Reflect How Good INBIOGEN's (KRX:101140) Earnings AreINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. We think that...Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Net income: ₩8.17b (up ₩12.6b from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩11,270, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 73% over the past three years.分析記事 • May 22Solid Earnings Reflect INBIOGEN's (KRX:101140) Strength As A BusinessINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. Investors are...Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩12,380, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 72% over the past three years.Valuation Update With 7 Day Price Move • May 02Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₩12,620, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 74% over the past three years.Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩5,980, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 7x in the Luxury industry in South Korea. Total loss to shareholders of 89% over the past three years.お知らせ • Mar 13INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2025INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea分析記事 • Jan 17Companies Like INBIOGEN (KRX:101140) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...New Risk • Jan 15New major risk - Revenue and earnings growthEarnings have declined by 1.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 1.9% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.4b revenue, or US$4.4m). Market cap is less than US$100m (₩66.8b market cap, or US$45.8m).Board Change • Jan 13No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Aug 09INBIOGEN Co., Ltd. announced that it expects to receive KRW 30.00000036 billion in fundingINBIOGEN CO.,Ltd announced a private placement of 15,957,447 convertible preferred shares at KRW 1,880 per share for gross proceeds of KRW 30,000,000,360 on August 8, 2022. The transaction will include participation from new investor Scan No. 1 Association. The transaction is by way of third party capital increase. The payment date for the shares is expected on October 28, 2022. The transaction has been approved by board of directors of the company. The preferred shares are registered and 100% convertible from October 29, 2023 - September 29, 2032. The convertible preferred shares are issued at 10% discount.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩1,830, the stock trades at a trailing P/E ratio of 22.2x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 50% over the past three years.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₩1,835, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 59% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Sep 01INBIOGEN CO.,Ltd announced that it has received KRW 15 billion in fundingOn August 31, 2021, INBIOGEN CO.,Ltd closed the transaction. The company issued KRW 15,000,000,000 in the transaction.お知らせ • Jun 01INBIOGEN CO.,Ltd announced that it has received KRW 23.300002 billion in funding from Bucket Studio Co., Ltd.On May 31, 2021, INBIOGEN CO.,Ltd (KOSE:A101140) closed the transaction.分析記事 • Mar 26Is INBIOGENLtd (KRX:101140) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...お知らせ • Mar 18INBIOGEN CO.,Ltd, Annual General Meeting, Mar 31, 2021INBIOGEN CO.,Ltd, Annual General Meeting, Mar 31, 2021, at 10:30 Korea Standard Time.Is New 90 Day High Low • Feb 18New 90-day low: ₩3,580The company is down 48% from its price of ₩6,860 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 17% over the same period.分析記事 • Jan 31Introducing INBIOGENLtd (KRX:101140), A Stock That Climbed 95% In The Last Five YearsINBIOGEN CO.,Ltd ( KRX:101140 ) shareholders might understandably be very concerned that the share price has dropped...Is New 90 Day High Low • Jan 31New 90-day low: ₩3,600The company is down 46% from its price of ₩6,680 on 02 November 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period.お知らせ • Dec 04BTONE CO.,Ltd announced that it expects to receive KRW 25.00000128 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of 4,340,278 registered convertible preferred stock at an issue price of KRW 5,760 per share for gross proceeds of KRW 25,000,001,280 on December 2, 2020. The transaction will include participation from JJ Fund. The company will raise funding through third party allotment. The preferred stock will be fully convertible into the 4,340,278 registered common stock of the company at a conversion price of KRW 5,760 per share. The conversion period of the preferred stock will be from February 19, 2022 to January 19, 2031. The preferred stock will be issued at discount of 10%. The transaction is expected to close on February 19, 2021 and expected date of issuance of new shares is March 05, 2021. The security issued in the transaction will be subject to hold period of one year. The transaction was approved by the board of directors of the company.お知らせ • Nov 26BTONE CO.,Ltd announced that it expects to receive KRW 20 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of series 7 Non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 20,000,000,000 on November 25, 2020. The transaction will include participation from JJ 1 Fund. The bonds will mature on January 29, 2024 and will carry 1% interest coupon and 2% yield to maturity. The bonds will be fully convertible into the 2,762,812 registered common stock of the company at a conversion price of KRW 7,239 per share. The conversion period of the bonds will be from January 29, 2022 to December 29, 2023. The bonds will be issued at its par value. The transaction is expected to close on January 29, 2021 and subscription date is November 27, 2020. The transaction was approved by the board of directors of the company.Is New 90 Day High Low • Nov 04New 90-day high: ₩7,290The company is up 87% from its price of ₩3,900 on 06 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 10.0% over the same period.Is New 90 Day High Low • Oct 19New 90-day high: ₩4,570The company is up 25% from its price of ₩3,650 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 7.0% over the same period.お知らせ • Oct 17BTONE CO.,Ltd announced that it expects to receive KRW 20 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of series 6 Non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 20,000,000,000 on October 16, 2020. The transaction will include participation from Hoyeon 3 Fund. The bonds will mature on November 30, 2023 and will not carry 1% interest coupon and 2% yield to maturity. The bonds will carry lump sum redemption on its maturity. The bonds will be fully convertible into the 5,357,621 registered common stock of the company at a conversion price of KRW 3,733 per share for 12.75% stakes in the company. The conversion period of the bonds will be from November 30, 2021 to October 30, 2023. The bonds will be issued at its par value. The transaction is expected to close on November 30, 2020 and subscription date will be October 21, 2020. The transaction was approved by the board of directors of the company.収支内訳INBIOGEN の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSE:A101140 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 265,444-18,1283,280031 Dec 256,297-1,4193,682030 Sep 257,80426,1514,6022230 Jun 257,73715,0294,9232231 Mar 257,3129,5625,642-631 Dec 247,04116,1225,686030 Sep 246,436-6,5494,975730 Jun 245,483-1,2715,272731 Mar 245,7175,9305,2611431 Dec 236,24111,8595,739830 Sep 236,17437,3376,371230 Jun 237,59429,4656,639231 Mar 239,394-54,4196,869331 Dec 2210,420-116,9496,521430 Sep 2212,796-17,5407,925630 Jun 2212,585-25,6638,1292331 Mar 2211,6984,3068,3212631 Dec 2110,48194,1258,7002530 Sep 219,029-55,1067,5312230 Jun 219,965-45,4216,887531 Mar 2110,518-2,1906,044031 Dec 2010,218-45,0785,492030 Sep 2010,384-20,7514,264030 Jun 2011,2561033,830031 Mar 2010,52112,2173,285031 Dec 199,79513,1242,393030 Sep 198,87319,9661,743030 Jun 196,7537,368-446031 Mar 196,3451,536-663031 Dec 187,5661,664-790030 Sep 186,8362,060-258030 Jun 186,665-8271,381031 Mar 185,999-1,1321,744031 Dec 177,077-1,2111,883030 Sep 178,347-1,5182,477030 Jun 178,134-1,9172,578031 Mar 179,678-2,0372,649031 Dec 1611,545-2,2563,207030 Sep 1611,970-2,3682,398030 Jun 1611,436-5,5545,092031 Mar 1610,064-5,6174,760031 Dec 158,865-5,6864,540030 Sep 158,862-5,0034,75021質の高い収益: A101140は現在利益が出ていません。利益率の向上: A101140は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A101140は利益を出していないが、過去 5 年間で年間19.6%の割合で損失を削減してきた。成長の加速: A101140の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A101140は利益が出ていないため、過去 1 年間の収益成長をLuxury業界 ( 19.3% ) と比較することは困難です。株主資本利益率高いROE: A101140は現在利益が出ていないため、自己資本利益率 ( -12.68% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YConsumer-durables 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/09 00:19終値2026/08/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋INBIOGEN Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • Nov 21Statutory Profit Doesn't Reflect How Good INBIOGEN's (KRX:101140) Earnings AreINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. We think that...
Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Net income: ₩8.17b (up ₩12.6b from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
分析記事 • May 22Solid Earnings Reflect INBIOGEN's (KRX:101140) Strength As A BusinessINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. Investors are...
New Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (₩5.4b revenue, or US$3.6m). Market cap is less than US$100m (₩80.7b market cap, or US$53.7m).
New Risk • Apr 04New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩6.3b (US$4.2m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (₩6.3b revenue, or US$4.2m). Market cap is less than US$100m (₩88.0b market cap, or US$58.2m).
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩9,800, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 10x in the Luxury industry in South Korea. Total loss to shareholders of 13% over the past three years.
お知らせ • Mar 17INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
Valuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩9,060, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 12x in the Luxury industry in South Korea. Total loss to shareholders of 25% over the past three years.
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,130, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 24% over the past three years.
New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₩113.7b market cap, or US$78.7m).
分析記事 • Nov 21Statutory Profit Doesn't Reflect How Good INBIOGEN's (KRX:101140) Earnings AreINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. We think that...
Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Net income: ₩8.17b (up ₩12.6b from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩11,270, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 73% over the past three years.
分析記事 • May 22Solid Earnings Reflect INBIOGEN's (KRX:101140) Strength As A BusinessINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. Investors are...
Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩12,380, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 72% over the past three years.
Valuation Update With 7 Day Price Move • May 02Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₩12,620, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 74% over the past three years.
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩5,980, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 7x in the Luxury industry in South Korea. Total loss to shareholders of 89% over the past three years.
お知らせ • Mar 13INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2025INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
分析記事 • Jan 17Companies Like INBIOGEN (KRX:101140) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
New Risk • Jan 15New major risk - Revenue and earnings growthEarnings have declined by 1.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 1.9% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.4b revenue, or US$4.4m). Market cap is less than US$100m (₩66.8b market cap, or US$45.8m).
Board Change • Jan 13No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Aug 09INBIOGEN Co., Ltd. announced that it expects to receive KRW 30.00000036 billion in fundingINBIOGEN CO.,Ltd announced a private placement of 15,957,447 convertible preferred shares at KRW 1,880 per share for gross proceeds of KRW 30,000,000,360 on August 8, 2022. The transaction will include participation from new investor Scan No. 1 Association. The transaction is by way of third party capital increase. The payment date for the shares is expected on October 28, 2022. The transaction has been approved by board of directors of the company. The preferred shares are registered and 100% convertible from October 29, 2023 - September 29, 2032. The convertible preferred shares are issued at 10% discount.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩1,830, the stock trades at a trailing P/E ratio of 22.2x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 50% over the past three years.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₩1,835, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 59% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Sep 01INBIOGEN CO.,Ltd announced that it has received KRW 15 billion in fundingOn August 31, 2021, INBIOGEN CO.,Ltd closed the transaction. The company issued KRW 15,000,000,000 in the transaction.
お知らせ • Jun 01INBIOGEN CO.,Ltd announced that it has received KRW 23.300002 billion in funding from Bucket Studio Co., Ltd.On May 31, 2021, INBIOGEN CO.,Ltd (KOSE:A101140) closed the transaction.
分析記事 • Mar 26Is INBIOGENLtd (KRX:101140) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
お知らせ • Mar 18INBIOGEN CO.,Ltd, Annual General Meeting, Mar 31, 2021INBIOGEN CO.,Ltd, Annual General Meeting, Mar 31, 2021, at 10:30 Korea Standard Time.
Is New 90 Day High Low • Feb 18New 90-day low: ₩3,580The company is down 48% from its price of ₩6,860 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 17% over the same period.
分析記事 • Jan 31Introducing INBIOGENLtd (KRX:101140), A Stock That Climbed 95% In The Last Five YearsINBIOGEN CO.,Ltd ( KRX:101140 ) shareholders might understandably be very concerned that the share price has dropped...
Is New 90 Day High Low • Jan 31New 90-day low: ₩3,600The company is down 46% from its price of ₩6,680 on 02 November 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period.
お知らせ • Dec 04BTONE CO.,Ltd announced that it expects to receive KRW 25.00000128 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of 4,340,278 registered convertible preferred stock at an issue price of KRW 5,760 per share for gross proceeds of KRW 25,000,001,280 on December 2, 2020. The transaction will include participation from JJ Fund. The company will raise funding through third party allotment. The preferred stock will be fully convertible into the 4,340,278 registered common stock of the company at a conversion price of KRW 5,760 per share. The conversion period of the preferred stock will be from February 19, 2022 to January 19, 2031. The preferred stock will be issued at discount of 10%. The transaction is expected to close on February 19, 2021 and expected date of issuance of new shares is March 05, 2021. The security issued in the transaction will be subject to hold period of one year. The transaction was approved by the board of directors of the company.
お知らせ • Nov 26BTONE CO.,Ltd announced that it expects to receive KRW 20 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of series 7 Non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 20,000,000,000 on November 25, 2020. The transaction will include participation from JJ 1 Fund. The bonds will mature on January 29, 2024 and will carry 1% interest coupon and 2% yield to maturity. The bonds will be fully convertible into the 2,762,812 registered common stock of the company at a conversion price of KRW 7,239 per share. The conversion period of the bonds will be from January 29, 2022 to December 29, 2023. The bonds will be issued at its par value. The transaction is expected to close on January 29, 2021 and subscription date is November 27, 2020. The transaction was approved by the board of directors of the company.
Is New 90 Day High Low • Nov 04New 90-day high: ₩7,290The company is up 87% from its price of ₩3,900 on 06 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Oct 19New 90-day high: ₩4,570The company is up 25% from its price of ₩3,650 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 7.0% over the same period.
お知らせ • Oct 17BTONE CO.,Ltd announced that it expects to receive KRW 20 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of series 6 Non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 20,000,000,000 on October 16, 2020. The transaction will include participation from Hoyeon 3 Fund. The bonds will mature on November 30, 2023 and will not carry 1% interest coupon and 2% yield to maturity. The bonds will carry lump sum redemption on its maturity. The bonds will be fully convertible into the 5,357,621 registered common stock of the company at a conversion price of KRW 3,733 per share for 12.75% stakes in the company. The conversion period of the bonds will be from November 30, 2021 to October 30, 2023. The bonds will be issued at its par value. The transaction is expected to close on November 30, 2020 and subscription date will be October 21, 2020. The transaction was approved by the board of directors of the company.